GH SecretagoguesCompoundableS

Ipamorelin

NNC 26-0161

Ipamorelin is a selective pentapeptide growth hormone secretagogue and ghrelin receptor agonist notable for stimulating robust GH release with minimal effect on cortisol or prolactin — making it one of the most selective and well-tolerated GHRP compounds. Frequently combined with CJC-1295 for synergistic GH pulse amplification and sustained IGF-1 elevation. Compoundable with prescription.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
4
Research grade
S
Community score
145

Trend index

Trackers
3,002

Overview

About Ipamorelin

Ipamorelin is a selective pentapeptide growth hormone secretagogue and ghrelin receptor agonist notable for stimulating robust GH release with minimal effect on cortisol or prolactin — making it one of the most selective and well-tolerated GHRP compounds. Frequently combined with CJC-1295 for synergistic GH pulse amplification and sustained IGF-1 elevation. Compoundable with prescription.

Category
GH Secretagogues
Regulatory status
Compoundable
Also known as
NNC 26-0161
Self-reports
102

Community

What 102 users report

102 community reports

Positive 98% · Neutral 2% · Negative 0%

Most reported benefits

Energy
236
Sleep
236

Most reported side effects

Water retention
2
Headache
2

Dose distribution

Median: 200–400 mcg · Most common: 200–400 mcg

0–25
0
25–50
0
50–100
12
100–200
63
200–400
137
400–600
22
600–1000
0
1000–2000
0
2000+
2

How repeat users are trending

Among repeat reporters, 98% said they felt similar to their last entry, 2% more positive, and 0% more negative.

Overall, repeat reporters leaned similar or mixed compared to their previous entry.

Median gap between entries: 51 days · Based on 44 repeat reporters

Research

Cited research (2)

Help

Frequently asked

What do PeptIQ users report about Ipamorelin?

This page summarizes 102 anonymized self-reports from PeptIQ users who track Ipamorelin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Ipamorelin?

2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Ipamorelin safe to use?

This wiki does not assess safety or recommend use. Ipamorelin is listed as Compoundable. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Ipamorelin?

Research, primarily in animal models, suggests Ipamorelin may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Ipamorelin?

Ipamorelin is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Ipamorelin as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Ipamorelin?

The safety and effectiveness of Ipamorelin have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Ipamorelin?

While there are over 200 published studies on Ipamorelin, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source